Alexandra Gerlach, Senior Content Producer

The agent continues to show promising clinical benefit despite being pulled from the market in 2023.

Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study.

Pharmacy experts share the benefits of the annual Oncology Pharmacists Connect meeting.

Combining benmelstobart and anlotinib shows promise for patients with squamous non-small cell lung cancer.

Kevin Chen, PharmD, MS, BCOP, CPP, highlighted key thoracic cancer advances from the 2025 ASCO Annual Meeting.

Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.

Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.

Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment of cutaneous malignancies.

Jolynn Sessions, PharmD, BCOP, FHOPA, shares her experience as a clinical pharmacist and the value of the Oncology Pharmacists Connect meeting.

Victoria Nacher, PharmD, BCOP, offers key insights about the evolving treatment landscape for hematologic malignancies.

The emergence of biomarkers plays a critical role in the growing success of treatment.

Tim Mok, PharmD, BCOP, BCPS, discusses emerging advancements in treatment of leukemia and lymphoma.

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

New executive orders and legislation aim to lower prescription drug costs and enhance access to pharmacist services for seniors across the US.

The investigational blood test achieved 99% sensitivity and specificity.

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanubrutinib for treatment-naive patients with CLL/SLL harboring del(17p).

Pembrolizumab gains FDA approval as a groundbreaking neoadjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Mitomycin intravesical solution is the first FDA-approved treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Significant challenges persist, particularly in low- and middle-income countries.

Meloxicam injection gains FDA approval for effective management of moderate-to-severe pain, offering a nonopioid alternative in pain control strategies.

Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for patients with relapsed/refractory multiple myeloma without maintenance treatment.

The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy.

Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk.

Experts share insights on patient discussions and adverse effect management strategies in HER2 breast cancer.

Explore the latest advancements in myelofibrosis treatment, focusing on JAK inhibitors and pegylated interferons for improved patient outcomes.

The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases.

Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors.

Experts discuss BiTE therapy in treating lung cancers, focusing on innovative agents like tarlatamab and amivantimab, and their toxicity management.

MRD testing transforms multiple myeloma treatment, guiding personalized strategies and improving patient outcomes through innovative testing methods.